The effect of pravastatin on acute rejection after kidney transplantation - A pilot study

Transplantation

Volumn 61, Issue 10, 1996, Pages 1469-1474

  Katznelson, Steven ^a,c   Wilkinson, Alan H ^b   Kobashigawa, Jon A ^b   Wang, Xiu Ming ^b   Chia, David ^b   Ozawa, Mikki ^b   Zhong, Hui Ping ^b   Hirata, Masaru ^b   Cohen, Arthur H ^b   Terasaki, Paul I ^b   Danovitch, Gabriel M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOSPORIN; LIPID; LOW DENSITY LIPOPROTEIN; OKT 3; PRAVASTATIN; PREDNISONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CYCLOSPORINE; CYTOTOXICITY, IMMUNOLOGIC; ENZYME INHIBITORS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PILOT PROJECTS; PRAVASTATIN; PREDNISONE;

EID: 9344254902     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199605270-00010     Document Type: Article

References (38)

1. Ong CS, Pollock CA, Caterson RJ, et al. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine 1994; 73: 215.
2. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84: 985.
3. Massy ZA, Chadefaux-Vekemans B, Chevalier A, et al. Hypercholesterolemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994; 9: 1103.
4. Isoneimi H, Larsson E, Tufveson G. Strategies in chronic rejection of transplanted organs: a current view on pathogenesis, diagnosis, and treatment. Transplant Proc 1989; 21: 1435.
5. Dimeny E, Fellstrom B, Larsson E, et al. Chronic vascular rejection and hyperlipidemia in renal transplant patients. Clin Transplant 1993; 7: 482.
6. Dimeny E, Fellstrom B, Larsson E, et al. Hyperlipidemia in renal transplant recipients: is there a linkage to chronic rejection? Transplant Proc 1993; 25: 2065.
7. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 1992; 11: S124.
8. Meiser BM, Wenke K, Thiery J, et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc 1993; 25: 2077.
9. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation in vitro studies with inhibitors of HMGCoA reductase. Atherosclerosis 1993; 101: 117.
10. Hidaka V, Eda T, Yonemoto M, et al. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992; 95: 87.
11. Kobashigawa JA, Katznelson S, Laks H, et al. Impact of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
12. Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 1991; 266: 12216.
13. Cutts JL, Bankurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl enzyme A reductase by lovastatin. Int J Immunopharmacol 1989; 11: 863.
14. Cutts JL, Scallen TJ, Watson J, Bankhurst. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139: 550.
15. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990; 145: 244.
16. Kreuzer J, Bader J, Jahn L, et al. Chemotaxis of the monocyte line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991; 90: 203.
17. Lye WC, Hughes K, Leong SO, et al. Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients; effect of treatment with pravastatin. Transplant Proc 1995; 27: 977.
18. Cheung AK, DeVault GA Jr, Gregory MC. A prospective study on the treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993; 3: 1884.
19. Triandl O, Reading S, Franz M, et al. Treatment of hyperlipidemic kidney graft recipients with lovastatin: effect on LDL-cholesterol and lipoprotein (a). Nephron 1992; 62: 394.
20. Kasiske BL, Tororice KL, Heim-Duthoy KL, et al. Lovastatin treatment of hypercholesterolemia in renal transplant in renal transplant recipients. Transplantation 1990; 49: 95.
21. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82(suppl IV): 281.
22. Vanhaecke J, Van Cleemput J, Van Lierde J, et al. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994; 58: 42.
23. East C, Grundy SM, Jones PH, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47.
24. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplantation. JAMA 1988; 260: 239.
25. Yoshimura N, Oka T, Okamoto M, et al. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94.
26. Cohen AH, Border WA, Rejfer J, et al. Interstitial Tamm-Horsfall protein in rejecting renal allografts: identification of morphologie pattern of injury. Lab Invest 1984; 50: 519.
27. Solez K, Axelson RA, Benediktsson H, et al. International standardization for the histological diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
28. Nast CC, Danovitch GM, Ettenger RB. Aspiration cytology in the evaluation of renal transplants. In: Progress in reproductive and urinary tract pathology, vol. II. Philadelphia: Field and Wood, 1990; 123.
29. Wang XM, Terasaki PI, Rankin GW Jr, et al. A new microcellular cytotoxicity tested based on calcein AM release. Hum Immunol 1993; 37: 264.
30. Ballantyne CM. Lipids and cyclosporin A. Transplant Immunol Lett 1992; 8: 4.
31. Hanas E, Totterman TH. Circulating T-lymphocyte subsets and NK-like cells in renal transplant patients: patterns associated with rejection. Nephrol Dial Transplant 1989; 4: 735.
32. Cooksey G, Robbins RA, Blamey RW, et al. Natural killer cells in renal allograft rejection. Br J Surg 1984; 71: 874.
33. Totterman TH, Hanas E, Bergstrom R, et al. Immunologic diagnosis of kidney rejection using FACS analysis of kidney rejection infiltrating functional and activated T and NK subsets. Transplantation 1989; 47: 817.
34. Lefkowitz M, Jorkasky D, Korwbluth J. Increase in natural killer activity in cyclosporine-treated renal allograft recipients during rejection. Human Immunol 1987; 19: 139.
35. Kirby JA, Givan AI, Sheton BK, et al. Renal allograft rejection: possible involvement of antibody-dependent cell-mediated cytotoxicity. Transplantation 1990; 50: 225.
36. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425.
37. Sinensky M, Beck LA, Leonard S. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem 1990; 265: 19937.
38. McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13: 439.